Arecor Therapeutics plc (FRA:6UI)

Market Cap	44.64M +43.6%
Revenue (ttm)	1.03M -22.9%
Net Income	220.65K
EPS	0.01
Shares Out	n/a
PE Ratio	143.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	483
Open	0.7400
Previous Close	0.8600
Day's Range	0.7400 - 0.8600
52-Week Range	0.5050 - 0.9350
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 12, 2026

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 33
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6UI

Financial Performance

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error